Skip to content
Screener

UroGen Pharma URGN Q1 2025 Annual earnings

Reported May 12, 2025 · Before market open

Revenue$20.3MMiss by $3.0M
EPS-$0.92Miss by $0.09
Revenue estimate$23.3M
EPS estimate-$0.83

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$90.6M
EPS estimate$0.10

Financials

Q1 2025

Income statement

See full
Revenue$20.3M+7.8%
Net income-$43.8M-35.8%

Balance sheet

See full
Cash & equivalents$104.0M-20.9%
Total debt$126.4M+27.6%
Total equity-$46.5M-15.8%
Total assets$247.6M+23.5%

Cash flow

See full
Operating cash flow-$42.0M-32.4%
CapEx$44.0K—
Free cash flow-$42.1M-32.6%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$509.8M-5.9%
Enterprise value$532.13M+4.4%
P/S5.5×-0.9×

Profitability

See full
Net margin-150.7%+41.9pp
FCF margin-116.9%+28.3pp

Returns & leverage

See full
Current ratio5.6×-1.8×

Segments

By product

See full
Jelmyto$20.3M+7.8%

FAQ

When did UroGen Pharma report Q1 2025 earnings?
UroGen Pharma (URGN) reported Q1 2025 earnings on May 12, 2025 before market open.
What were UroGen Pharma's Q1 2025 revenue and EPS?
UroGen Pharma reported revenue of $20.3M and eps of $-0.92 for Q1 2025.
Did UroGen Pharma beat estimates in Q1 2025?
Revenue missed the consensus estimate of $23.3M by $3.0M. EPS missed the consensus estimate of $-0.83 by $0.09.
How did UroGen Pharma's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 7.8% from $18.8M a year earlier and eps grew 5.2% from $-0.97.
Where can I find UroGen Pharma's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001437749-25-015955) and the 10-K/A periodic report (0001437749-25-013839) directly on SEC EDGAR. The filing index links above go to sec.gov.